Dissemin is shutting down on January 1st, 2025

Links

Tools

Export citation

Search in Google Scholar

Role of anti-diabetic drugs as therapeutic agents in alzheimer’s disease

This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Question mark in circle
Preprint: policy unknown
Question mark in circle
Postprint: policy unknown
Question mark in circle
Published version: policy unknown

Abstract

Recent data have suggested a strong possible link between Type 2 Diabetes Mellitus and Alzheimer's disease (AD), although exact mechanisms linking the two are still a matter of research and debate. Interestingly, both are diseases with high incidence and prevalence in later years of life. The link appears so strong that some scientists use Alzheimer's and Type 3 Diabetes interchangeably. In depth study of recent data suggests that the anti diabetic drugs not only have possible role in treatment of Alzheimer's but may also arrest the declining cognitive functions associated with it. The present review gives an insight into the possible links, existing therapeutics and clinical trials of anti diabetic drugs in patients suffering from AD primarily or as co-morbidity. It may be concluded that the possible beneficial effects and usefulness of the current anti diabetic drugs in AD cannot be neglected and further research is required to achieve positive results. Currently, several drug trials are in progress to give conclusive evidence based data. Abbreviations: AD = Alzheimer's disease; T2DM = Type2 Diabetes Mellitus; ADD = Antidiabetic drugs; ADDLs = Aβ-Derived Diffusible Ligands; Aβ = Amyloid β; BBB = Blood brain barrier; AMPK = AMP-activated protein kinase; CNS = Central nervous system; BACE-1 = β-secretase; PPARγ = Peroxisome proliferator activated receptor gamma; GLP-1 = Glucagon-like peptide-1; DPP-4 = Dipeptidyl peptidase-4; SAMP8 = Senescence-accelerated prone; SGLTs = Sodium glucose co-transporters